Induction of mucosal tolerance to antigens
US10195269B2 · kind B2 · utility
0Cited by
38References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2016 |
| Grant date | Feb 5, 2019 |
| Priority date | — |
| Expiry date | Oct 21, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/577
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3+ and/or IL-10 and/or TGF-β producing regulatory T-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.